Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a biopharmaceutical company developing and commercializing treatments for neurological diseases, with a focus on sleep and wake disorders, rare epilepsy, and neurobehavioral conditions. Its commercial product, WAKIX (pitolisant), is approved in the United States for… From the company’s description.
Over the twelve months to Sep 30, 2026, Harmony Biosciences Holdings, Inc. reported revenue of $989.36M, up 19.8% from a year earlier, and net income of $178.60M. Its operating margin was 22.2%, and operations generated $323.04M in cash. In fiscal 2025, it reported revenue of $868.45M, up 21.5% from fiscal 2024, and net income of $158.69M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Harmony Biosciences Holdings, Inc. does
In the company’s own words
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a biopharmaceutical company developing and commercializing treatments for neurological diseases, with a focus on sleep and wake disorders, rare epilepsy, and neurobehavioral conditions. Its commercial product, WAKIX (pitolisant), is approved in the United States for excessive daytime sleepiness and cataplexy in adults and children six years and older with narcolepsy; the company reported $868.5 million in WAKIX net product revenue for 2025. Its development programs include pitolisant for idiopathic hypersomnia, Prader-Willi syndrome and myotonic dystrophy type 1, next-generation pitolisant formulations, and candidates for narcolepsy and rare epilepsy, including EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Harmony operates through its wholly owned subsidiaries and organizes its portfolio around sleep/wake, rare epilepsy and neurobehavioral franchises. It licenses pitolisant from Bioprojet and acquired Epygenix Therapeutics to add its epilepsy programs. Its website is https://www.harmonybiosciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PLYMOUTH MEETING, PA
- Fiscal year end
- December
- CIK
- 1802665
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Harmony Biosciences Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Harmony Biosciences Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Harmony Biosciences Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Harmony Biosciences Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Harmony Biosciences Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”